



HOA Physicians. Front Left to right: Dr. James Lin, Dr. Jody Jordan, Dr. Lovie Bey, Back Left to right: Dr. Victor Vigil, Dr. P. Lorraine Sanchez, Dr. Malcolm Purdy



Dr. Paul Duncan
one of the founding
physicians of
Hematology Oncology
Associates

Hematology-Oncology Associates, P.C. (HOA) is a subspecialty hematology oncology physician group practice established in 1977 in a private practice model. Their mission statement today is the same as it was in 1976 when HOA was established: "To provide the highest level of care for our patients using professional skill and knowledge, with compassion and respect,

while preserving dignity in a comfortable and caring environment."

The hematologists and oncologists at HOA include:

- **Victor Vigil**, who joined HOA in 1993 and **Lorraine Sanchez** who joined HOA in 1994. Native New Mexicans, both are fluent in Spanish. They both earned their medical degrees at UNM, and completed internal medicine residencies and hematology-oncology fellowships at UNM.
- **Malcolm Purdy** who joined HOA in 1999, was a faculty member of UNM SOM based at the AVAH. He completed his hematology-oncology and bone marrow transplant fellowship at the University of

New Mexico Cancer Care Alliance Highlights Hematology Oncology Associates

Colorado Hospitals system. He was the chief resident in medicine at UNM in 1982-83.

- **Jim Lin** joined HOA in 2003 from his faculty position at UTMB-Galveston of 12 years. He is a graduate of the University of Minnesota and completed his hematology-oncology fellowship at Yale then continued at Sloan Kettering as a research fellow for three years.

- **Lovie Bey** is a Kansas native and a graduate of the University of Kansas. She completed her internal medicine and hematology-oncology fellowship at Tulane in New Orleans. She joined HOA in January 2006.

- **Jody Jordan** is also a native New Mexican. She completed her MD at UNM. She studied internal medicine at UT San Antonio followed by her hematology-oncology fellowship at Georgetown University at the Vince Lombardi Cancer Center. She practiced oncology in New Zealand for 6 months before joining HOA in March 2006.

- **Paul Duncan** completed his post graduate internal medicine and hematology-oncology fellowship at UNM and an additional post fellowship year at the Royal Marsden Hospital in London, UK. He is a graduate of the University of Washington and completed his military obligation with the USPHS in Anchorage, Alaska before coming to New Mexico. He established HOA in 1976.

HOA was committed to advancing the knowledge base of oncology even before the NMCCA was formed. The founders of HOA set up the means to participate in national clinical trials starting in the 1980's. At that

time, HOA realized the tremendous potential benefit to all the people of NM and facilitated this vision by forming an organization that provides a broader accessibility to clinical trials. Thus, HOA worked together with key physicians in the community and the leaders of UNM, Presbyterian Healthcare System, Lovelace Healthcare System, the Veteran's Hospital and the former St. Joseph's Hospital System to help make the NMCCA a reality. Dr. Vigil has been on the Board of Directors and Executive Committee since its inception. Drs. Purdy and Lin are key members of the NMCCA's Medical and Scientific Review Committee and volunteer long hours to review clinical trials. HOA is firmly committed to the NMCCA because of the incredible proven benefits it brings to the people of NM. Participation in the NMCCA is an important mechanism that allows HOA to offer state of the art cancer care in a private practice setting.

One of the facets of their practice, which distinguishes HOA from other oncology practices in New Mexico, is their Cancer Genetics Program. Dr. Duncan was selected by ASCO to represent New Mexico at the initial "Train the Trainer" course in clinical cancer genetics in 1997. He has become a resource for physicians and patients throughout New Mexico. To date over 400 families have been evaluated and 60 unique deleterious mutations identified. In 2007 HOA became an affiliate of the City of Hope clinical cancer genetics program. HOA is currently enrolling subjects on a City of Hope Protocol-96144: Molecular Genetic Studies in Cancer Patients and their Relatives with Cancer. At this time 55 patients/families are part of this protocol.

Please visit HOA's website at www.hoanm.com.

INSIDE AT A GLANCE

| | |
|--|---|
| <i>I was Given 10 Months to Live</i> | 2 |
| <i>February 2009 :</i> | |
| <i>Clinical Trials Awareness Month</i> | 2 |
| <i>Protocols Available at HOA</i> | 3 |

| | |
|---|---|
| <i>Upcoming Events</i> | 4 |
| <i>NMCCA 6th Annual Meeting</i> | 4 |
| <i>LLS Joins NMCCA as Affiliate Participant</i> . . | 5 |
| <i>LLS Challenges the Editor</i> | 5 |

| | |
|---|---|
| <i>H.E.R.O. Breakfast 2009</i> | 6 |
| <i>NMCCA Welcomes New Board Members, Participants and Affiliate Members</i> | 7 |
| <i>Recipes for Cancer Patients During and After Treatment</i> | 8 |

I Was Given 10 Months to Live

By Patricia Contreras



In 2001, I was diagnosed with gastric cancer of the stomach and a total gastrectomy was performed. I did well until a routine gynecological checkup in 2004, discovered a gastric carcinoma tumor (approx 9 x 5 cm) along the cervix wall. I was told by three different surgeons that surgery

was not possible due to the location and depth of the tumor along the wall and the presence of lymph node spread. I was given 10 months to live. My oncologist was Dr. Malcolm Purdy at Hematology Oncology Associates (HOA) and he offered me a clinical trial using an experimental drug called S1101. I agreed to participate in the study. The purpose of the study was to test the safety and effectiveness

of this new experimental drug S-1 in combination with Cisplatin in patients with advanced gastric stomach cancer that had failed standard therapy. I received the treatment at Dr. Purdy's office. I was closely monitored by the physicians and the research nurse at HOA. They were uplifting and I received quality care. It is important that I did what the study asked. I took pills for 21 days and then received my Cisplatin. My physician was always checking for side effects. Routine tests were done to monitor the effects of treatment. After the first month of therapy the tumor shrunk in half. By the end of the year the tumor had apparently dissolved completely. I truly believe if I had not participated in the study I would not have survived the gastric cancer recurrence.

Study number TPU S1101: A Phase I/II, Open Label, Nonrandomized, Dose-Finding Safety, Tolerance, Pharmacokinetic and Efficacy Study of Orally Administered S-1 in Combination with Cisplatin in Patients with Advanced Gastric Cancer

The data collected on Study number TPU S1101: A Phase I/II, Open Label, Nonrandomized, Dose-Finding Safety, Tolerance, Pharmacokinetic and Efficacy Study of Orally Administered S-1 in Combination with Cisplatin in Patients with Advanced Gastric Cancer will be presented at the American Society of Clinical Oncology 2009 Gastrointestinal Cancer Symposium on January 15, 2009. The abstract was not available at press time. For information about TPU S1101 visit the ASCO website at www.asco.org.

FEBRUARY 2009 Clinical Trials Awareness Month

New Mexico Cancer Care Alliance is sponsoring Clinical Trial Awareness Month during the month of February. Only 3 percent of adult cancer patients in the United States participate in clinical trials. This is far fewer than the number needed to answer the most pressing cancer questions. Some of the barriers for the general public to participate in a clinical trial include:


- Lack of awareness of clinical trials.
- Lack of access to trials.
- Fear, distrust, or suspicions of research
- Practical or personal obstacles.
- Insurance or cost problems.
- Unwillingness to go against personal physician's wishes.

A survey of almost 6,000 people with cancer showed that 85 percent of people with cancer were either unaware or unsure that participation in clinical trials was an option, though 75 percent of

these people said they would have been willing to enroll had they known it was possible. Of those who were aware of the clinical trial option, most declined to participate because they believed common myths about clinical trials. They either thought that:

- The medical treatment they would receive in a clinical trial would be less effective than standard care.
- They might get a placebo
- They would be treated like a "guinea pig"
- Their insurance company would not cover the cost.

People who participated in a clinical trial said they were treated with dignity and respect and that the quality of care they received was "excellent" or "good" and 86 percent said that their treatment while on a clinical trial was covered by insurance.



During Clinical Trials Awareness Month, NMCCA plans to address these issues by visiting our participating sites to share more information about clinical trials. We will focus on raising the public's awareness and educating them about cancer clinical trials, what they are and are not, the possible benefits of participation, the mechanisms in place for patient safety, the availability of trials in New Mexico, the insurance coverage law in the state, encouraging people to take an active role in their health care options, and recognizing cancer clinical trial participants.

To learn more about cancer clinical trials and what trials are available in New Mexico visit our website at www.nmcca.org.



Diplomates, American Board of Internal Medicine and Medical Oncology
A Founding Member of the New Mexico Cancer Care Alliance
30+ Years of Excellence
Founded in 1976

Lovie Bey, MD
Paul R. Duncan, MD, FACP
Jody L. Jordan, M.D.
James T. Lin, MD

Malcolm H. Purdy, MD
P. Lorraine Sanchez, MD
Victor V. Vigil, MD

Protocols Available at HOA

BREAST PROTOCOLS

SWOG S0307, A Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

SWOG S0221, Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Pac given either every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.

SWOG S0226, Phase II Randomized trial of anastrozole versus anastrozole and fulvestrant as first line therapy for post menopausal women with metastatic breast cancer.

ECOG PACCT-1, Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment. The TAILORx Trial.

NSABP B-42, A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

IBCSG 24-02, A Phase III trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer

SWOG S0622, Phase II studies of two different schedules of Dasatinib (NSC-732517) in bone metastasis predominant metastatic breast cancer

ECOG E5103, A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

ACOSOG Z1031, A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

COLON PROTOCOLS

NCCTG N0147, A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

Pharm 20060141, A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer. SPIRITT Trial. (Amgen)

INST 3304C, A Phase II Trial of Using Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Patients with Newly Diagnosed Resectable Rectal Cancer.

NSABP R-04, Phase III Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum

PANCREAS PROTOCOLS

Pharm AMP-019, A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® plus Gemcitabine versus Gemcitabine plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)

GENITO-UROLOGICAL/ PROSTATE PROTOCOLS

CALGB 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Pharm AT-101-CS-202: An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men with Hormone Refractory Prostate Cancer (HRPC) Only Second Line Cohort open.

Pharm AT-101-CS-205: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination with Docetaxel and Prednisone versus Docetaxel and Prednisone in Men with Chemotherapy-Naïve Metastatic HRPC

E2805, A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma.

LUNG PROTOCOLS

INST 0601C, A Randomized Phase II Protocol of Erlotinib Versus Standard Platinum-Based Chemotherapy Patients with Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung.

ECOG E1505, A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)

Page 3 of 4 HOA Clinical Trials are open through the New Mexico Cancer Care Alliance

LYMPHOMA PROTOCOLS

CALGB 50303, Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in untreated de Novo Diffuse Large B Cell Lymphomas

MYELOMA PROTOCOLS

S0309, Myeloma Specimen Repository Protocol, Ancillary. (SWOG)

OTHER PROTOCOLS

City of Hope Protocol 96144, Molecular Genetics Studies in Cancer Patients and Their Families

INST 0535C, Prospective study of Clinical Predictors of Survival in Cancer Patients with Metastatic Solid Tumors.

INST 0553C, A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.

UPCOMING EVENTS

Volunteer Facilitator Training 2/6 - 2/8

Facilitate a support group offering hope to cancer survivors & caregivers; no experience necessary

Girls' Night Out - 2/19

Join us for fun, food & conversation with women of all ages and cancer diagnoses!

Men's Night Out - 3/12

Casino night for men of all ages and cancer diagnoses—wives & partners welcome!



Contact People Living Through Cancer at 505-242-3263 or www.pltc.org for more information

Think Pink!

The University of New Mexico Lobos men's and women's basketball teams are helping to promote breast cancer awareness with the upcoming Think Pink! Basketball Games.

Lady Lobos will play Brigham Young University on February 17 at 6:00 p.m., and the men's team will play Texas Christian University on

February 24 at 6:30 p.m. Both games will be at The Pit, with special halftime tributes to breast cancer survivors. Fans are encouraged to wear pink to show support for this disease, which affects one in eight women nationwide.



NM House vs. Senate Basketball Game

Come help New Mexico's lawmakers raise cancer funds while shooting hoops at the always hard-fought House vs. Senate game. Established more than 15 years ago, the annual event has raised thousands of dollars for the University of New Mexico Cancer Center. This year, the game will be held at 7 p.m. on February 18 at the New Mexico School for the Deaf in Santa Fe. Admission is \$5, and all proceeds go to the UNM Cancer Center.

NMCCA 6th Annual Meeting

New Mexico Cancer Care Alliance recently held its sixth annual meeting that brought together many of the participants and affiliates.

NMCCA has had an exciting year. NMCCA worked with the University of New Mexico Cancer Center to successfully submit the National Cancer Institute New Mexico Minority-Based Community Clinical Oncology Program (MBCCOP) Competitive Application; this allows the physicians within our network to continue to offer National Cancer Institute (NCI) cooperative group studies. The NMCCA sites accrued 241 patients onto our trials, which exceeded our goal by 46 patients. This brings the total number of patients we have helped since we became operational in the fall of 2003 to

over 650. We continue to decrease the time it takes to open new clinical trials; and we have become more diligent in opening the right trials for our patients. The year end audited financial reports indicates that we are breaking even, consistent with the initial business plan.

Special awards were given to Presbyterian Healthcare Services for the community site with the most MBCCOP accruals, Hematology Oncology Associates for the community site with the most overall accruals, and UNM Cancer Center for the NMCCA site with the most accruals.

NMCCA continues to grow our network, and in May 2008, Memorial Medical Center in Las Cruces became an Institutional Class D participant.

The list of Affiliate Participants now includes People Living Through Cancer, Casa Esperanza, Leukemia & Lymphoma Society New Mexico/El Paso Chapter and the Central New Mexico Susan G. Komen for the Cure. This coming year we plan to add additional participants outside of the Rio Grande corridor and to continue our ongoing efforts on our awareness and outreach events in the upcoming year.

DID YOU KNOW?
Teamwork. At the Annual Meeting, the participants and affiliates work together to provide the best cancer treatment options for New Mexicans.



New Mexico Cancer Care Alliance Staff
Front left to right: Linda Kondziolka, Business Manager; Vicki Witte, Clinical Trial Assistant; and Ruby Allen, Community Research Coordinator
Back left to right: Andrea Yost, Data Coordinator; Maria Naranjo, Regulatory Coordinator; Debbie Putt, Communications and Outreach Manager, and Teresa Stewart, Executive Director, and Martha Howell, Regulatory Coordinator.



Teresa Stewart presents Valerie Parks from the University of New Mexico an award



Geraldine Esquivel, The American Cancer Society; Dr. Victor Vigil, HOA, and Dr. Claire Verschraegen, UNM

Thank You to our Sponsors!

Millennium Pharmaceuticals, Inc., Genetech BioOncology and ImClone Systems, Inc.

The Leukemia & Lymphoma Society joins NMCCA as an Affiliate Participant



One million North Americans and their families are living with blood cancer, and The Leukemia & Lymphoma Society (LLS) is dedicated to a vision: by 2015, the vast majority of people diagnosed with a blood cancer will be cured or will manage their illness with a good quality of life. Nationally, LLS funds research to save lives. Locally, the New Mexico/El Paso Chapter of LLS maintains an office in Albuquerque, and serves patients and families throughout the state and El Paso.

Becoming an NMCCA affiliate participant was natural for LLS. "LLS is committed to research, and we are strong advocates of clinical trials," says Executive Director Deborah Hoffman. "We educate patients and health professionals about the latest advances in blood cancer research, and our new Therapy Acceleration Program is designed to speed discoveries from laboratories into new therapies for patients."

All services offered through LLS are free. Family support groups are offered, as are educational programs like "Getting the Best Cancer Care at Any Age," "Meet the Doctor," and "Welcome Back to School" for educators and parents of children with cancer. Patient financial aid provides up to \$500 annually to blood cancer patients for reimbursements for co-pays and transportation to treatment.

Fundraising programs include Team In Training, the #1 sports training program in the world, the Light The Night walk, Pennies For Patients, Chocolate & Beer Sensation, and Man & Woman of the Year. Check the comprehensive website at www.lls.org. For information contact Mikki Aronoff toll-free at 888-286-7846 or aronoffm@lls.org.

LLS Challenges The Editor



The ad sounded perfect. Tackle eight beautiful hiking trails in the most scenic areas of New Mexico. Meet new friends hiking under the watchful eye of a trained guide. Make the experience even more meaningful by doing it to honor patients fighting blood cancers.

The catch? Ah, there's always one of those. At an information meeting put on by The Leukemia & Lymphoma Society, my husband Dean and I discovered that to join Eight Great Hikes we'd have to fundraise...and we'd have to get up at 5:00 on Saturday mornings to meet fellow hikers at the trailhead before the suns began blazing. Intimidating, yes. But when we discovered that the money raised goes to researchers looking for blood cancer cures, plus financial aid and educational programs for cancer patients right here in New Mexico, we decided to give it a try.

Trader Joe's chocolate & good conversations. As an Indiana native, I never thought I'd find myself at the summit of an 11,301-ft. mountain and surviving. But last October 18th, Dean and I found ourselves at the top of Mt. Taylor with the most wonderful group of people you'd ever hope to meet. Our team bonded from the very first hike at Tent Rocks, and subsequently hiked at Jemez Falls, McCauley Hot Springs, the Dome Wilderness, Jack's Creek, Fourth of July Canyon, Nambe Lake and Chaco Canyon. Along the way we learned to love dark chocolate triangles from Trader Joe's and not to challenge cattle who think they have the right of way. Each hiker had a

reason for being there; either they had survived a bone marrow transplant just one year prior to the hikes, were hiking in memory of a loved one who had died from cancer, or hiking in honor of a cancer survivor. We all had the same goal.... support cancer research. I may have been the last one to the top of Mt. Taylor, but I did it and it felt wonderful. Well maybe not physically, but I felt like I was on top of the world!

My husband and I raised \$3,000 and our team raised over \$14,000. I would like to share our top 10 reasons for fundraising for LLS.

- #10. We like to hike.
- #9. We like to meet other crazy people
- #8. We hate cancer.
- #7. Dean's dad Bob Putt died from lymphoma in 1992.
- #6. Debbie's sister-in-law Renee Snook has lived with lymphoma for over 7 years.
- #5. We both work in the cancer field.
- #4. We support cancer research.
- #3. Research has improved survival outcomes for lymphoma
- #2. The Leukemia and Lymphoma Society provides millions of dollars for cancer research.
- #1. We hate lymphoma more than we dislike fundraising.

To learn more about hiking and other activities with The Leukemia & Lymphoma Society, go to www.teamintraining.org or call 505-872-0141.





honoring

our H.E.R.O.S

Helping to Enhance Research Oncology



HERO Recognition Breakfast Honoring Cancer Patients on Research Studies

April 3, 2009

A HERO Recognition Breakfast honoring cancer patients participating in research studies will be held April 3, 2009. HERO is an acronym for "Helping to Enhance Research in Oncology^(SM)". NMCCA believes any person who participates in a research study shows courage by volunteering for a new experimental treatment that may offer hope and possibly a cure to future generations. These people truly are heroes.

The 2009 HERO Recognition Breakfast will be held at the Embassy Suites Hotel and Conference Center, Albuquerque from 7:00 am to 9:00 am. The HERO Recognition Breakfast is a small but public way of recognizing and thanking cancer patients and their families for participating

on a research study. The breakfast also provides an opportunity to raise awareness of the importance of clinical trials to cancer research and advancing treatments; and the important role the human subjects play. The program will include two keynote speakers. Dr. Cheryl Willman, Director of the University of New Mexico Cancer Center will present an update from the 2009 New Mexico legislative session on the status of the proposed legislation to expand the current Clinical Trials Insurance Coverage Bill. The additional keynote speaker will be nationally known speaker and humorist, Dave Caperton. In his program, 'Healing Humor', Mr. Caperton will teach both the patients and healthcare providers ways to use

the healing power of compassionate humor and laughter to lower stress and to live every moment with purposeful joy.

The 2009 Hero Recognition Breakfast will have in attendance the patients and family members who will receive complimentary tickets and the medical and professional staff who served them. In the past, New Mexico political and community leaders have also attended.

NMCCA is dedicated to providing access to the most up-to-date clinical research studies in cancer treatment for New Mexico cancer patients and physicians.

For more information please contact Debbie at dputt@nmcca.org or 505-272-7819.

GIVE TO THOSE WHO GIVE

Patients and family members receive complimentary tickets to the breakfast and program.
Please consider being a sponsor of the 2009 HERO Recognition Breakfast.

For more information, contact NMCCA at 505-272-7813 or dputt@nmcca.org.

Yes!

I am pleased to contribute to the New Mexico Cancer Care Alliance

TWO WAYS TO GIVE:

1. Give Online: www.nmcca.org
2. Cut out form and mail check to:
P.O. Box 4428• Albuquerque, NM 87196

(Make checks payable to New Mexico Cancer Care Alliance)

Name: _____

Phone: _____

Address: _____

City _____

State: _____ Zip: _____

Email address: _____

My gift is for:

\$10 \$15 \$25 \$50 \$100 \$_____

I authorize the New Mexico Cancer Care Alliance to charge my gift to:

VISA MasterCard American Express

Account #: _____

Expiration date: _____

Signature: _____

Name as it appears on card: _____

Combined Federal Campaign

All Federal employees have the opportunity to contribute to the Combined Federal Campaign. If you are a Federal employee in Central or Northern New Mexico, you may donate to our campaign. Our charity code is 93229.

United Way Donor Option Plan

During your company's United Way campaign drive, you can specify your donation be given to New Mexico Cancer Care Alliance. For questions, call United Way at 505-247-3671.

New Mexico Cancer Care Alliance Welcomes New Board Members, Participants and Affiliate Members

The New Mexico Cancer Care Alliance continues to grow as the Board of Directors voted to approve Dava Gerard, M.D. from Presbyterian Healthcare Services, to serve as a board member and approved Dr. Sandra Mueller, M.D., PhD and Richard Mondragon, M.D, both with Petroglyph Pathology Services as Participants.

Additionally, the Central New Mexico Affiliate of Susan G. Komen for the Cure and The Leukemia & Lymphoma Society, New Mexico/El Paso Chapter were approved as Affiliate Participants. Affiliate Participants are groups involved with cancer treatment, research, support and education. Affiliates work with NMCCA's physician participants to increase knowledge of the role research may play in cancer treatments.

NMCCA looks forward to working with these new directors and participants and to the expertise that they bring to the organization.

New Mexico Cancer Care Alliance, a 501(c)(3) charitable organization, offers New Mexico cancer patients and physicians access to the most up-to-date clinical research studies in cancer treatment. Our network of the major healthcare systems in Northern, Central, and Southern New Mexico and most of the community oncology professionals allows cancer patients to receive quality healthcare locally while increasing the knowledge of cancer care globally.



New Mexico Cancer Care Alliance

Sharing Your Thoughts

Have you participated in a clinical trial? Would you like to share a few words about your experience?

If so, we'd love to include your thoughts in our newsletters.

Contact Debbie Putt at dputt@nmcca.org
Or write to: NMCCA, 801 University Blvd. SE, Suite 102, Albuquerque, NM 87106.



Don't Miss Out!

Sign up to Receive the **NMCCA Community Newsletter Today!**

email Debbie Putt at dkputt@nmcca.org or register on-line at www.nmcca.org

Electronic versions of NMCCA newsletters available at www.nmcca.org/whatsnew/newsletters.htm

NMCCA Community Newsletter is a publication of the New Mexico Cancer Care Alliance. Any submissions can be sent to Debbie Putt, Communications and Outreach Manager dputt@nmcca.org • Phone 505 272-7819 • Fax 505 272-7799

Editor: Debbie Putt
Graphic Artist: Kathy Montoya, Montoya Creative

Recipes for Cancer Patients During and After Treatment

Food for Neutropenia (low white count)

Loaded Potatoes

Makes 6 servings

- 1 (32 oz) bag frozen hash brown potatoes
- 2 large eggs
- 3 large egg whites
- 2 cups skim milk
- 4 tablespoons margarine, melted
- Salt and pepper to taste
- ½ teaspoon onion powder
- 2 cups shredded reduced-fat Cheddar cheese
- ½ cup nonfat plain yogurt

Preheat oven to 350°. Place the potatoes in a 1 ½-quart shallow baking dish coated with nonstick cooking spray. Bake for 15 minutes. Meanwhile, combine the eggs, egg whites, milk, margarine, salt and pepper, and onion powder. Remove the potatoes from the oven. Sprinkle with Cheddar cheese, tossing with a fork to mix. Pour the milk mixture over the potatoes. Return to the oven and bake for 30 to 40 minutes longer or until the potatoes are light brown and firm to touch.

Doc's note: If neutropenic, do not use salsa or green onions.

Source: Eating Well Through Cancer, Easy Recipes & Recommendations During & After Treatment, Holly Clegg & Gerald Milello, M.D.

Food for Diarrhea

Easy Banana Bread

Makes 16 slices

- 1 (8-ounces) package reduced-fat cream cheese, softened
- 1 cup sugar
- 3 medium bananas, mashed
- 1 large egg, beaten
- 2 large egg whites
- 2 cups biscuit baking mix
- ½ teaspoon ground cinnamon

Preheat oven to 350°. Coat a 9x5x3 inch loaf pan with nonstick cooking spray. In a mixing bowl, cream together the cream cheese and sugar until light. Beat in the bananas, egg, and egg whites. Stir in the biscuit mix and cinnamon until just blended. Turn into the prepared loaf pan. Bake for 45 minutes to 1 hour, until a toothpick inserted in the center comes out clean. Cool in pan for 15 minutes.



801 University Blvd., SE
Suite 102
Albuquerque, NM 87106

